Key Publications

Pinho BR, Duarte AI, Canas PM, Moreira P, Murphy MP, Oliveira JMA* (2019) The interplay between redox signalling and proteostasis in neurodegeneration: In vivo effects of a mitochondria-targeted antioxidant in Huntington’s disease mice. Free Radical Biology and Medicine (in press)


Soares TR, Reis SD, Pinho BR, Duchen MR, Oliveira JMA* (2019) Targeting the proteostasis network in Huntington's disease. Ageing Research Reviews 49:92-103


Pinho BR, Reis SD, Hartley RC, Murphy MP, Oliveira JMA* (2019) Mitochondrial superoxide generation induces a parkinsonian phenotype in zebrafish and huntingtin aggregation in human cells. Free Radical Biology and Medicine 130:318-327


Reis SD, Pinho BR, Oliveira JMA* (2017) Modulation of molecular chaperones in Huntington’s disease and other polyglutamine disorders. Molecular Neurobiology, 54:5829-5854


Pinho BR, Reis SD, Guedes-Dias P, Leitão-Rocha A, Quintas C, Valentão P, Andrade PB. Santos MM, Oliveira JMA* (2016) Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: therapeutic implications for Parkinson's disease. Pharmacological Research, 103:328-339


Guedes-Dias P, Pinho BR, Soares TR, de Proenca J, Leitao-Rocha A, Duchen MR, Oliveira JMA* (2016) Mitochondrial dynamics and quality control in Huntington's disease. Neurobiology of disease, 90:51-7


Guedes-Dias P, de Proenca J, Soares TR, Leitao-Rocha A, Pinho BR, Duchen MR, Oliveira JMA* (2015) HDAC6 inhibition induces mitochondrial fusion, autophagic flux and reduces diffuse mutant huntingtin in striatal neurons. BBA Molecular Basis of Disease 1852:2484-2493


Leitão-Rocha A, Guedes-Dias P, Pinho BR, Oliveira JMA* (2015) Trends in mitochondrial therapeutics for neurological disease. Current Medicinal Chemistry, 22(20): 2458-2467


Almalki AA, Alston CL, Parker A, Simonic I, Mehta SG, He L, Reza M, Oliveira JMA, Lightowlers RN, McFarland R, Taylor RW, Chrzanowska-Lightowlers ZMA (2014) Mutation of the human mitochondrial phenylalanine-tRNA synthetase causes infantile-onset epilepsy and cytochrome c oxidase deficiency. BBA Molecular Basis of Disease 1842:56-64


Guedes-Dias P, Oliveira JMA* (2013) Lysine deacetylases and mitochondrial dynamics in neurodegeneration. BBA Molecular Basis of Disease 1832:1345-1359


Bruni F, Gramegna P, Oliveira JMA, Lightowlers RN, Chrzanowska-Lightowlers ZMA (2013) REXO2 Is an Oligoribonuclease Active in Human Mitochondria. PLoS ONE 8(5): e64670. doi:10.1371/journal.pone.0064670


Pinho BR, Santos MM, Fonseca-Silva A, Valentão P, Andrade PB, Oliveira JMA* (2013) How mitocondrial dysfunction affects zebrafish development and cardiovascular function: An in vivo model for testing mitochondria-targeted drugs. British Journal of Pharmacology 169:1072-1090


Oliveira JMA* (2011) Techniques to investigate neuronal mitochondrial function and its pharmacological modulation. Current Drug Targets. 12, 762-773


Oliveira JMA & Lightowlers RN (2010) Could successful (mitochondrial) networking help prevent Huntington's disease? EMBO Molecular Medicine. 2:487-489


Oliveira JMA* (2010) Nature and cause of mitochondrial dysfunction in Huntington's Disease: Focusing on huntingtin and the striatum. Journal of Neurochemistry. 114:1-12


Oliveira JMA* (2010) Mitochondrial bioenergetics and dynamics in Huntington’s disease: tripartite synapses and selective striatal degeneration. Journal of Bioenergetics and Biomembranes. 42:227-34


Oliveira JMA* & Gonçalves J (2009) In situ mitochondrial Ca2+ buffering differences of intact neurons and astrocytes from cortex and striatum. Journal of Biological Chemistry 284(8): 5010-5020


Canas PM, Porciúncula LO, Cunha GM, Silva C, Machado N, Oliveira JMA, Oliveira CR, Cunha RA (2009) Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via P38 MAP Kinase pathway. Journal of Neuroscience 29(47):14741-14751


Oliveira JMA, Jekabsons MB, Chen S, Lin A, Rego AC, Gonçalves J, Ellerby LM and Nicholls DG (2007) Mitochondrial dysfunction in Huntington’s disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice. Journal of Neurochemistry 101: 241-249


Oliveira JMA, Chen S, Almeida S, Riley R, Gonçalves J, Oliveira CR, Hayden MR, Nicholls DG, Ellerby LM and Rego AC (2006) Mitochondrial-dependent Ca2+ handling in Huntington’s disease striatal cells: Effect of HDAC inhibitors. Journal of Neuroscience 26(43):11174-11186